Franceinfo: ESMO congress unveils phase 3 melanoma trial results
The European Society for Medical Oncology opened its annual congress in Madrid with data showing an experimental messenger RNA cancer vaccine reduced the risk of recurrence or death by 42% in melanoma patients, franceinfo reported.
Key Clinical Takeaways:
- Trial results presented at the ESMO congress in Madrid evaluate an mRNA vaccine combined with standard immunotherapy.
- Data from a phase 3 trial involving more than 1,000 postoperative melanoma patients show a 42% reduction in recurrence or death.
- The personalized therapeutic vaccine uses genetic mutations extracted directly from each patient’s individual tumor.
More than 30,000 oncologists gathered in Madrid on Friday as complete data from the first therapeutic mRNA cancer vaccine trial went on public release. Professor Caroline Robert, a melanoma specialist at Gustave Roussy, described the development as a therapeutic revolution during the congress proceedings. Robert included several of her own patients in the study.
Jean-Claude, a 78-year-old patient treated at Gustave Roussy after undergoing surgery for a melanoma on his skull, received the combination treatment. The preparation of the injection was tailored specifically to his tumor mutations. Scans and radiological evaluations show no recurrence over a three-year period following the intervention.
Custom mRNA Vaccines Train Immune Systems to Destroy Tumors
The therapeutic approach manufactures each injection individually by sequencing the genetic mutations found within the patient’s specific excised tumor. This customized blueprint trains the body’s immune system to recognize and destroy rogue malignant cells more effectively than standard systemic therapy alone.
Participants in the phase 3 trial received standard immunotherapy paired with the patient-specific mRNA vaccine. Clinical investigators are concurrently testing the same personalized platform in active clinical trials targeting lung, bladder, and kidney cancers.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.